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1001-48 Nitroglycerin Reduces Blood Viscosity: A Novel 
Mechanism to Explain the Enhancement of Nutrient 
Blood Flow to Ischemic Zones 
Jian-Pino Bin. Howard Leong-Poi, Nicholas G. Fisher, Amol M. Takalkar, Kevin Wei, 
Sanjiv Kaul, University of virginia, Charlottesville, Virginia. 
Introduction: Nitroglycerin (NTG) is thought to relieve ischemia by increasing coronary 
blood flow (CBF) via dilation of conductance vessels or from collaterals, or by its effects 
on hamodynamics. We have shown, however, that increases in hyperemic CBF are lim- 
ited mainly by capillary or myocardial vascular resistance (MVR), which depends on 
blood viscosity. We therefore hypothesized that enhancement of nutrient blood flow to 
ischemic zones during NTG are secondary not to decreases in stenosis resistance (SR) 
or collateral flow, but to reduced blood viscosity. 
Methods: We studied 5 open chest dogs with a critical LAD or LCx stenosis (group 1 ). To 
eliminate collateral flow, the LCx was stanosed while the LAD was occluded in 5 other 
dogs (group 2). NTG (0.2-0.5p_gokg-lomin -1) was infused into the left main coronary 
artery to minimize effects on systemic hemodynamics. At baseline and during NTG, 
mean aortic pressure (MAP), distal coronary pressure (dCP), right atrial pressure (RAP), 
CBF (ultrasonic flow probes), myocardial blood flow (MBF) (rediolabeled microspheres), 
and whole blood viscosity (WBV) were determined. SR and MVR were calculated using 
MAP-dCP/CBF and dCP-RAP/CBF, respectively. MCE was performed to determine myo- 
cardial blood volume (MBV). 
Resulta: No changes in hemodynamics were seen after NTG compared to baseline in 
either group of dogs. In group 1 dogs, there was no significant decrease in stanosis resis- 
tanca or increase in MBV after NTG. A significant decrease in WBV (17:t:15 %, p=0.01), 
and a concurrent decrease in MVR in the ischemic bed (1.8_+0.4 vs 1.3t-0.2, p=0.03), 
however, was associated with an increase in MBF in the ischemic bed (0.8:t:0.3 vs 
1.4±0.5, p=0.01). Similarly, despite elimination of collateral flow to the stanosed bed, a 
18+14% decrease in WBV (p=0.04) and an increase in MBF in the ischemic bad (0.7±0.2 
vs 1.2tO.4, p--0.01) was found in group 2 dogs with NTG. 
Conclusion: Increases in MBF during NTG are not reliant on changes in stenosis resis- 
tance, MBV, or coUateral flow, but are secondary to reductions in blood viscosity which 
enhances microcirculatory red blood cell velocity. This phenomenon might explain in part 
the anti-ischemic effect of the drug. 
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1002-38 Prshospital Fibrinolysis: Is It Safe, Feasible, and 
Efficient in a Large Urban North American Center? 
Robert C. Welsh. Andrew Travers, Terry Sosnowski, Randall Williams, Manohara 
Senaratne, Zaheer Lakhani, Paul W. Armstrong, University of Alberta, Edmonton, 
Alberta, Canada. 
Despite evidence of the importance of time to treatment in ST elevation AMI delays initi- 
ating fibrinolysis remain significant. Fibrinolytic mega-triats over the past decade have 
consistently demonstrated failure to improve time to treatment (median 2.8 h). Canadian 
data (3523 AMI patients in 74 cantres) identifies continuing delay in door to needle times 
(median 62 min., FASTRAC II, 2000), Our participation in the ongoing ASSENT 3+ sub 
study (TNK-tPA _+ heparin .0Z enoxapadn) provided a unique opportunity to assess the 
safety, feasibility and efficiency of pre-hospltal fibdnolysis in a North American Metropoli- 
tan center, where such a program was previously non-existant. 
Methods: 320 ACLS paramedics (32 ambulances) were trained to assess enrollment cri- 
teria, obtain/transmit 12-lead ECG's in potential fibrinolytic candidates. Physician ECG 
over-read and telephone support permitted pre-hospital fibrinolysis. A detailed screening 
and enrollment database was used to collect information on all paramedic-identified 
fibrinolytic andidates. 
Results: 30% (75/250) of screened patients (median age 58y, 21% anterior AMI, and 
80% male) received pre-hospital fibrinolysis over 12 months (09/2000 to 08/2001). Pre- 
hospital therapy was associated with no significant medication errors, major hemorrhage 
or intra cranial hemorrhage; 32% underwent urgent angiography. 175 failed to meet 
enrollment criteria (52/250clinicaL, 110/250 -ECG, and 13/250 failed transmission). 
Median time to treatment of 92 minutes was 58 minutes earlier than established stan- 
dards in the participating region and compares favorably to the recently results of 
ASSENT 3 (3 hours). 
Conclualon: This initial single center experience demonstrates that pre-hcspital fibrinol- 
ysis by trained paramedics with remote physician support and over-read of ECG is safe, 
feasible and efficient with 30% of paramedic screened patients receiving pre-hospital 
fibrinolysis without significant medication error or major hemorrhage. This pre-hospital 
treatment strategy (bolus fibrinolytic) coupled with a one-hour reduction in time to treat- 
ment would be expected to modulate major benefit and is deserving of further study in 
other centers. 
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1002-39 A Randomized Study to Investigate the Hemostatlc 
Effect of Tenect~plase (TNK-t-PA) Versus Aiteplase (rt- 
PA) and Streptokinase (SK) in Acute Myecardlal 
Infarction 
Felicita Andreofti, Luigi M. Biasucoi, Silvano Berioli, Giovanna Crespi, Eugenia De 
Marco, Annalise Porto, Daniela Albiero, Attilio Mased, Antonio G. Rebuzzi, on behalf of 
Investigator Group, Catholic University, Rome, Italy, Boehringer-lngelheim, Florence, 
Italy, 
Background: Although thrombolyfic treatment is associated with a significant reduction in 
the risk of death after acute myocardial infarction (MI), it is also associated with a signifi- 
cant incidence of hemorrhagic complications and with the short-tarm recurrence of 
angina and MI. A possible contdbufion to these events is the hamostatic derangement 
elicited by fibrinolytic agents which, however, may differ from agent to agent. The aim of 
this study was to compare the hemostatic effects of tenecteplase (TNK-tPA), altaplase 
(rt-PA) and streptokinase (SK) by measuring the plasma concentrations of procoagulant 
and fibrinolytic-activity markers before and after thrombolysis. 
Methods: We assessed the levels of thrombin-antithrombin (TAT), prothrombin fragment 
F1+2, plasminogen activator inhibitor-1 (PAl-l) and plasmin-antiplasmin (PAP) in 45 
patients with acute MI randomized to receive either TNK-tPA (30-50 mg weight adjusted 
in a single bolus), rt-PA (100 mg over 90 minutes), or SK (1,500,000 IU over 1 hour), in 
addition to heparin (8001U/h) and aspirin. Blood samples were taken on admission (prior 
to randomization), and after 2, 6 and 24 hours from the start of thrombolysis. 
Results: A significant increase in TAT levels from admission values was observed at 2h in 
patients treated with SK (p<0.05). PAl-1 and PAP levels were significantly reduced in 
patients treated with TNK-tPA compared to rt-PA and SK (median & range PAl-1 at 6h: 
59.4 ng/ml (20.7-135.9) vs 102.3 ng/ml (32.7-187.7) and 106.5 ng/ml (58.7-168.4), 
respectively, p<0.05; PAP at 2h: 5526 mg/I (132-7153) vs 6547 mg/I (2494-9172) and 
7068 mg/I (174-9839), p<0.05; PAP at 6h: 4151 mg/I (1982-5759) vs 6105 mg/I (611- 
8089) and 5833 mg/I (1311-9212), p<0.05), 
Conclusion: Our data suggest that TNK~t-PA has reduced effects on the hemoststic sys- 
tem compared to rt-PA and SK. This might altow less aggressive ant/coagulation during 
and after thrombolysis with TNK-tPA, thereby reducing the risk of bleeding and allowing 
safer access to rescue or facilitated percutaneous coronary interventions. 
1002-40 Compar i son  o f  the Frequency and Outcomes of  
Investigator Assessed Recurrent MI Versus Clinical 
Event Commit tee  (CEC) Adjudicated Recurrent MI in 
Acute MI Trials: A TIMI 14 and TIMI 9 Substudy 
Sabina A. Murohv, Robed P. Giugliano, Graham Wong, Christopher P. Cannon, Elliott M. 
Antman, Michael Gibson, Harvard Clinical Research Institute, Boston, Massachusetts, 
Brigham & Women's Hospital, Boston, Massachusetts. 
Background: Mortality rates in acute MI trial are low, and recurrent MI (re MI) or death/re 
MI have emerged as a critical endpoints. However, many of these trials used investigator 
assessment of reMI at the clinical site rather than clinical event committee (CEC) adjudi- 
cation. We hypothesized that site assessed reMI would be more frequent than CEC adju- 
dicated reMI, and that mortality would be higher in patients with a CEC adjudicated reMI. 
Methods: Data were drawn from the TIMI 9A, 9B and 14 acute MI trials. All pts with a 
site assessed MI and a CEC review of the reMI were included in the substudy (n=534), 
There were 573 reMIs in the study (total greater due to multiple reMIs in some pts). 
Results: ReMI was confirmed by adjudication in 40.1% (220/548) of site assessed 
reMIs. The CEC confirmed 25 reMIs the sites did not identify. Mortality by 30 days was 
higher in pts with a CEC confirmed reMI than in pts with a reMI assessed by the site only 
(13.27% vs 7.72%, p=0.04) (Figure). Pts who were not classified as an MI by either site 
or the CEC of reMI had lower mortality (5.32%) than those with a CEC reMI (p<0,001) 
and only trended lower compared with those with a site reMI only (p=0,078). Conclu- 
sion: CEC review of reMI results in lower rates of reMI compared with clinical site 
assessment. The 30 day mortality rate associated with a CEC confirmed reMI was higher 
than in pts with no MI, while there was only a trend for mortality for site assessed reMI to 
differ from no MI. 
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